Advanced Cell Technology Receives Approval From Data Safety Monitoring Board (DSMB) To Initiate Treatment Of Third Patient Cohort In All Three Clinical Trials
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the
field of regenerative medicine, announced today that the independent
Data and Safety Monitoring Board (DSMB) overseeing the Company’s three
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the independent Data and Safety Monitoring Board (DSMB) overseeing the Company’s three ongoing stem cell clinical trials in the United States and Europe has authorized the Company to move forward with enrolling and treating the patients in the next cohort of each of the trials. Per each trial’s protocol, the first patient of “cohort 3” will be injected with 150,000 human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells. This represents a fifty percent increase in the dose of RPE cells as compared to the previously treated cohort of patients. The first patients treated at this escalated dose will be evaluated, with interim DSMB review after six weeks, at which time the determination to continue treating additional patients at this dosage will be made. Additionally, the DSMB has authorized the Company to proceed with treating patients in the two U.S. trials as part of additional cohorts recently approved by the FDA. In particular, the FDA approved the addition of two new cohorts of four patients each – one cohort for each of the Stargardt’s Macular Dystrophy (SMD) and dry age-related macular degeneration (dry AMD) trials – which can include patients with better vision. The specific protocol for these “cohort 2a” patients establishes eligibility for enrollment based on visual acuity as good as 20/100. Previous patients enrolled in the trials have visual acuity no better than 20/400 and ranging to patients whose visual acuity had deteriorated to hand-motion only sight. In addition to establishing the safety of the transplanted RPE cells, the opportunity to treat patients earlier in the course of progression of these diseases improves the likelihood of enrolling patients having a greater number of photoreceptors that, while inactive due to loss of the native RPE layer, are dormant but able to be rescued by the reestablishment of a functional RPE layer from the transplanted cells. Enrollment of the additional patients as part of cohort 2a will be simultaneous with enrollment of patients in the 150,000 cell dose cohort 3 patients.